Search research articles
Contact Us
Filters
Showing results (791-800 of 853) with videos related to
Page
of 86
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
S Banerjee, G Rustin, J Paul, et al.
Nature Medicine
|
August 10, 2000
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
F R Khuri, J Nemunaitis, I Ganly, et al.
Cancer Research
|
March 17, 2006
10th Biennial Helene Harris Memorial Trust meeting
Frances R Balkwill, Alan Ashworth, Robert C Bast, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2007
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
Kim Appleton, Helen J Mackay, Ian Judson, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Stan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
A Horwich, D T Sleijfer, S D Fosså, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
The New England Journal of Medicine
|
June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
Peter C Fong, David S Boss, Timothy A Yap, et al.
Page
of 86
Search research articles
Search
Showing results (791-800 of 853) with videos related to
Sort By:
Page
of 86
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
S Banerjee, G Rustin, J Paul, et al.
Nature Medicine
|
August 10, 2000
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
F R Khuri, J Nemunaitis, I Ganly, et al.
Cancer Research
|
March 17, 2006
10th Biennial Helene Harris Memorial Trust meeting
Frances R Balkwill, Alan Ashworth, Robert C Bast, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
Sophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 11, 2007
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
Kim Appleton, Helen J Mackay, Ian Judson, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2011
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
Stan B Kaye, Jan Lubinski, Ursula Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 1997
Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
A Horwich, D T Sleijfer, S D Fosså, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
The New England Journal of Medicine
|
June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
Peter C Fong, David S Boss, Timothy A Yap, et al.
Page
of 86